Technology matters: The clinical utility of HPV mRNA testing compared to DNA testing


Developments in cervical cancer screening have dramatically decreased disease incidence and mortality over the past few decades - but have also added confusion concerning the roles and clinical applications of new technologies that detect human papillomavirus (HPV). How should clinicians approach these new testing methods so that they can provide better quality of life and treatment planning for their patients?

In this online supplement, E. Marshall Austin, MD, PhD offers insights on the many questions clinicians may have about HPV testing modalities, including:

  • What is the role of HPV in cervical cancer?
  • How do performance data compare for HPV DNA and mRNA tests?
  • What are the benefits of HPV mRNA testing?

Read this online supplement to learn more about the latest in developments in cervical cancer screening.

Download Supplement



Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit:
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit:
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit:
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
Related Content
© 2024 MJH Life Sciences

All rights reserved.